喹硫平与利培酮合并丙戊酸镁缓释片治疗躁狂症的对照研究

The control study of Quetiapine and Risperidone combined with magnesium valproate sustained release tablets in treatment of mania

目的:比较喹硫平和利培酮分别联合丙戊酸镁缓释片治疗躁狂症的疗效及安全性。方法:将65例躁狂症患者随机分为研究组和对照组,疗程6周。两组患者均服用丙戊酸镁缓释片,研究组患者给予喹硫平口服,对照组给予利培酮口服。以Beck-Rafaelsen躁狂量表(BRMS)与不良反应量表(TESS)评定疗效及不良反应。结果:6周末两组均有显著疗效,但1周末研究组BRMS评分下降速度更快(P<0.05),锥体外系反应(EPS)及内分泌改变均低于对照组(P<0.05)。结论:两组临床效果显著,疗效相当,但喹硫平联合丙戊酸镁缓释片起效快,不良反应少,安全性高。

Objective：To compare the effects and safety of Quetiapine and Risperidone combined with magnesium valproate sustained release tablets in the treatment of mania. Methods：65 cases of mania patients were randomly divided into the study group and the control group. Both groups of patients had taken magnesium valproate sustained release tablets for 6 weeks, the study group pa- tients were given Quetiapine, and the control group were received Risperidone. the effects were assessed with the BRMS and adverse effects with the TESS before treatment, at the end of the 1 st ,2nd,4th and 6th week treatment. Results： there were no significant differ ences between the study group and the control group in the effects at the end of the 6th week, but at the end of the 1 st week, the BRMS scores of the study group declined much quicker （P 〈 0.05）, EPS and endocrine changes were lower than the control group （ P 〈 0. 05）. Conclusions： the effects of two groups are significant and equivalent, however, the study group takes effect faster, less adverse effects and better safety.